Compare Repligen Corporation Common Stock (RGEN) vs Vanguard International High Dividend Yield ETF (VYMI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Vanguard International High Dividend Yield ETF — how do they compare? Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B), while Vanguard International High Dividend Yield ETF trades at $100.51 (market cap $22.80B). The key difference: Vanguard International High Dividend Yield ETF is far larger — about 2× Repligen Corporation Common Stock's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Vanguard International High Dividend Yield ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Vanguard International High Dividend Yield ETF for 51 Days on average.
| RGEN | VYMI | |
|---|---|---|
Market Cap | $11.14B | $22.80B |
Volume | 1,259,263 | 740,346 |
Sector | Health | Broad Market / Factor |
52-Week High | $194.57 | $107.13 |
52-Week Low | $102.87 | $84.45 |
Typical Hold Time | 0 Days | 51 Days |
Enterprise Value | $11.02B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
VYMI trades at $101.52, up 0.71% with a bearish technical signal from moving averages. The ETF shows strong institutional interest with Envestnet increasing holdings by 22% in Q2 2026. Recent news highlights VYMI's 29% one-year return and 3.61% dividend yield, outperforming peers with a 5-year average annual return of 14.13% according to Seeking Alpha on September 21, 2026.
The outlook remains positive with sector catalysts in financials, energy, and healthcare supporting dividend growth. Key risks include global market volatility and currency exposure. Analyst sentiment leans bullish with VYMI positioned as an attractive international dividend play amid rising global rates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Vanguard International High Dividend Yield ETF
VYMI is an index-based ETF that provides exposure to non-U.S. companies across developed and emerging markets that are characterized by high dividend yields. It tracks the FTSE All-World ex US High Dividend Yield Index, offering a diversified, low-cost way to capture international income while serving as a tactical hedge against U.S. market concentration.
Read more on VYMI →
